Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market
Hyderabad, India and Princeton, NJ, USA – Dr. Reddy’s Laboratories Ltd. along with its subsidiaries…
Dr. Reddy’s Laboratories Ltd
Dr. Reddy’s and RDIF commence clinical trials for Sputnik V vaccine in India
Hyderabad: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment…
Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries…
Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets
Hyderabad, India, October 5, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:…
Dr. Reddy’s Laboratories announces the launch of Cinacalcet Tablets in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. October 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124,…
Dr. Reddy’s announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. September 25, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE:…
Dr. Reddy’s Laboratories announces the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. September 7, 2020 – Dr Reddy’s Laboratories Ltd. (BSE:…
Dr. Reddy’s Laboratories enters hospital nutrition segment with Celevida Maxx in India
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY), today announced the entry…